High demand expected for new daily weight loss pill - The tablet could be a cheaper and more convenient alternative to ...

A new study shows that weight loss medication patients can experience hunger, eat well-balanced meals, and still make significant progress ...

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

A crisp fanatic who tipped the scales at a hefty 20 stone after munching through four packets a day has shed an incredible ...

Lisa Bernett, from Boreham Wood in Hertfordhire, used to eat four bags of crisps a day, as well as two takeaways a week that ...

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

Chief Executive David Ricks said the quarter was marked by robust sales for Zepbound and Mounjaro, in addition to momentum across other key medicines. Eli Lilly logged net income of $5.66 billion, or ...

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...